Biocon Executive and Leadership Team

Mohan Raj, the Chief Executive Officer at Biocon, directs the company's overarching strategy and market positioning. Raj focuses on driving Biocon's mission to deliver affordable healthcare solutions globally. This leadership role involves navigating complex regulatory landscapes and fostering innovation across the biopharmaceutical sector. Raj ensures alignment with the company's commitment to equitable access to life-saving medicines. The Chief Executive Officer oversees the strategic direction for all business units, including Generics, Biosimilars, Novel Biologics, and Research Services. By championing strategic partnerships and market expansion, Mohan Raj significantly contributes to Biocon's growth and its impact on patient lives worldwide. Raj's leadership ensures the company remains at the forefront of biopharmaceutical advancements.

Revathi Sakamuri, the Principal Chief Executive Officer at Biocon, spearheads critical strategic initiatives and operational excellence. Sakamuri guides the company's expansion in key therapeutic areas such as oncology, diabetes, and immunology. This executive function involves optimizing resource allocation and driving efficiency across all operational facets. Sakamuri ensures Biocon's continued leadership in the GLP-1 peptide market and its global reach. The Principal Chief Executive Officer's responsibilities encompass fostering a culture of innovation and ensuring the highest standards of quality in medicine development. By focusing on sustainable growth and market penetration, Revathi Sakamuri reinforces Biocon's position as a global biopharma leader committed to improving patient outcomes.

Shreehas Tambe, the Chief Executive Officer & Managing Director at Biocon, executes the company's strategic vision and operational management. Tambe drives the development and manufacture of high-quality, affordable medicines for chronic conditions, aligning with Biocon's core mission. This leadership position involves overseeing the integration of business units and ensuring seamless operations across Generics, Biosimilars, Novel Biologics, and Research Services. Tambe's focus includes expanding Biocon's global footprint and enhancing access to critical therapies. The Chief Executive Officer & Managing Director champions initiatives that strengthen Biocon's market leadership in biosimilar insulins and monoclonal antibodies. Through strategic oversight and operational discipline, Shreehas Tambe ensures Biocon's continued success and its commitment to serving a billion people with life-saving healthcare.

Arindam Chakrabarti, the Chief Financial Officer at Biocon, manages the company's financial strategy and fiscal health. Chakrabarti oversees all financial planning, reporting, and investment activities, ensuring resources are allocated effectively to support Biocon's growth and mission. This critical function involves maintaining financial stability while driving initiatives for affordable medicine development and global expansion. The Chief Financial Officer ensures robust financial controls and compliance with global accounting standards. Chakrabarti's leadership supports Biocon's commitment to providing equitable access to healthcare by optimizing financial performance. By guiding financial operations, Arindam Chakrabarti is instrumental in sustaining Biocon's position as a leading biopharmaceutical company.

Arun Gupta, the Chief Operating Officer at Biocon, directs the company's global manufacturing and supply chain operations. Gupta ensures the efficient and high-quality production of affordable medicines, supporting Biocon's mission to reach a billion people. This executive role involves optimizing operational workflows and implementing best practices across all production facilities. The Chief Operating Officer oversees the scaling of manufacturing capabilities to meet increasing global demand for generics and biosimilars. Gupta's focus includes enhancing operational efficiency and ensuring compliance with stringent international regulatory standards. By driving operational excellence, Arun Gupta plays a vital part in Biocon's ability to deliver life-saving therapies consistently and reliably across 120+ countries.

Mandar Ghatnekar, the Chief Technology Officer at Biocon, architects the company's technological infrastructure and innovation pipeline. Ghatnekar drives the adoption of cutting-edge technologies to enhance drug discovery, development, and manufacturing processes. This role is critical for maintaining Biocon's competitive edge in the biopharmaceutical industry, particularly in areas like biosimilars and novel biologics. The Chief Technology Officer oversees the integration of digital solutions and advanced analytics to optimize research services and product development. Ghatnekar ensures that Biocon's technological capabilities support the mission of providing affordable, high-quality medicines globally. By leading technological advancements, Mandar Ghatnekar directly contributes to Biocon's ability to address complex chronic conditions and expand healthcare access.